The promise of biosimilars was straightforward enough to fit on a campaign banner: near-identical versions of expensive biologic drugs, at significantly lower prices, increasing competition and reducing spending. The reality has been considerably more complicated, and the complications begin with the pricing architecture into which biosimilars must insert themselves — a system designed around branded biologics and resistant to the competitive dynamics that biosimilars are supposed to introduce.
Consider the reimbursement math. Medicare Part B reimburses most physician-administered drugs at ASP plus six percent. A reference biologic with an ASP of $5,000 generates a margin of $300 per administration. A biosimilar priced at a twenty percent discount — ASP of $4,000 — generates a margin of $240. The physician who prescribes the biosimilar saves the healthcare system money but earns $60 less per administration. The percentage margin is the same. The dollar margin is lower. For a busy oncology practice administering dozens of infusions per week, the aggregate difference is material.
CMS has attempted to address this arithmetic by reimbursing certain biosimilars at the reference brand’s ASP plus eight percent rather than the biosimilar’s own ASP plus six percent
. This temporary payment increase anchors the biosimilar’s reimbursement to the reference product’s higher ASP, ensuring that the prescribing physician earns at least as much — and potentially more — by choosing the biosimilar. The policy is a concession to the reality that reimbursement incentives, not just clinical equivalence, drive prescribing behavior in the physician-administered drug market.
But the reimbursement formula is only one layer of the pricing landscape. The rebate dynamics may matter more. Reference biologic manufacturers, facing biosimilar competition, have responded by increasing rebates to PBMs and commercial payers — offering larger discounts in exchange for exclusive or preferred formulary positioning that blocks biosimilar access. A reference biologic with a WAC of $6,000 and a forty percent rebate delivers a net cost of $3,600 to the payer. A biosimilar with a WAC of $4,800 and a fifteen percent rebate delivers a net cost of $4,080. The biosimilar has a lower list price and a higher net cost. The payer rationally prefers the reference product.
This dynamic — in which the incumbent’s rebate strategy neutralizes the entrant’s price advantage — has been widely observed in the biosimilar market and has confounded projections of rapid market share capture. Biosimilar manufacturers can respond by increasing their own rebates, but this compresses margins on products that are already priced below the reference. The rebate competition between reference biologics and biosimilars can reach a point where the biosimilar’s net price is competitive but its profitability is marginal, discouraging further investment in biosimilar development for that therapeutic category.
The ASP calculation itself creates a timing disadvantage for biosimilar entrants. A new biosimilar launches with no ASP history. CMS must establish an initial ASP based on early sales data, which may reflect launch pricing, introductory discounts, and low-volume economics that are not representative of steady-state pricing. The two-quarter lag means the biosimilar’s ASP-based reimbursement will not reflect market-level pricing until at least six months after launch. During this window, reimbursement uncertainty can deter early adoption — physicians and health systems may hesitate to prescribe a drug whose reimbursement rate is not yet established or may not cover acquisition costs.
The interchangeability designation adds another variable. Biosimilars designated as interchangeable by the FDA can be substituted at the pharmacy level without prescriber intervention, similar to generic substitution for small-molecule drugs. This regulatory status is valuable because it expands market access beyond prescriber choice. But interchangeability requires additional clinical data beyond what is needed for biosimilar approval, raising development costs and timelines. Manufacturers must decide whether the investment in interchangeability data is justified by the market access it provides — a calculation that depends on the competitive landscape, payer contracting dynamics, and state-level substitution laws that vary in implementation.
The 340B program interacts with biosimilar economics in ways that can either accelerate or impede adoption. Covered entities that purchase drugs at 340B ceiling prices and dispense them at market rates earn margin on the spread. For reference biologics with high WAC, the 340B spread can be substantial. If a biosimilar’s lower WAC produces a smaller 340B spread, covered entities face a financial disincentive to switch — even if the biosimilar costs less to the overall system. The entity’s margin shrinks when the cheaper drug is dispensed. This is a well-documented perverse incentive in the 340B program that applies to biosimilars with particular force.
The international experience offers both encouragement and caution. European markets have achieved substantially higher biosimilar penetration than the United States, driven by different reimbursement systems, stronger regulatory push for substitution, and less entrenched rebate-based contracting. The European model suggests that the obstacles to biosimilar adoption in the U.S. are structural rather than inherent — the drugs work, prescribers accept them, and patients tolerate them. The barriers are in the plumbing: a reimbursement architecture that rewards higher-cost products, a contracting system in which incumbents can outrebate challengers, and a regulatory pathway that imposes higher costs on the very products meant to provide lower-cost alternatives.
The biosimilar market is not failing. Products are launching, prices are generally below reference biologics, and adoption is growing — albeit more slowly than advocates projected. What the market reveals is that a product’s price advantage, however substantial, is insufficient to drive adoption when the surrounding pricing architecture creates countervailing incentives at every level. Reimbursement formulas, rebate competition, 340B dynamics, and prescriber switching costs form a network of obstacles that a lower price alone cannot overcome. The biosimilar discount paradox is that the system designed to reward lower-cost alternatives often rewards the more expensive incumbent instead.
